LAG3 and neoplasm: They have found that tumor-infiltrating immune cells comprise a previously unrecognized diversity of cell types, including CD8+ T cells predominantly expressing the checkpoint marker LAG3, rather than PDCD1 or CTLA4, suggesting that LAG3 is a potential candidate for ICB in patients with high-risk UM.